Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1963 1
1967 1
1972 1
1973 3
1974 3
1976 1
1977 5
1978 4
1979 1
1980 4
1981 4
1982 3
1983 1
1984 5
1985 12
1986 15
1987 7
1988 11
1989 7
1990 8
1991 3
1992 12
1993 4
1994 3
1995 6
1996 5
1997 13
1998 7
1999 12
2000 12
2001 13
2002 7
2003 12
2004 8
2005 11
2006 13
2007 12
2008 16
2009 8
2010 6
2011 12
2012 9
2013 10
2014 12
2015 18
2016 9
2017 17
2018 11
2019 8
2020 14
2021 16
2022 12
2023 15
2024 13
2025 6

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

439 results

Results by year

Filters applied: . Clear all
Page 1
Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children.
Gupta S, Rau RE, Kairalla JA, Rabin KR, Wang C, Angiolillo AL, Alexander S, Carroll AJ, Conway S, Gore L, Kirsch I, Kubaney HR, Li AM, McNeer JL, Militano O, Miller TP, Moyer Y, O'Brien MM, Okada M, Reshmi SC, Shago M, Wagner E, Winick N, Wood BL, Haworth-Wright T, Zaman F, Zugmaier G, Zupanec S, Devidas M, Hunger SP, Teachey DT, Raetz EA, Loh ML. Gupta S, et al. Among authors: kirsch i. N Engl J Med. 2025 Feb 27;392(9):875-891. doi: 10.1056/NEJMoa2411680. Epub 2024 Dec 7. N Engl J Med. 2025. PMID: 39651791 Free PMC article. Clinical Trial.
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial.
Spiegel JY, Patel S, Muffly L, Hossain NM, Oak J, Baird JH, Frank MJ, Shiraz P, Sahaf B, Craig J, Iglesias M, Younes S, Natkunam Y, Ozawa MG, Yang E, Tamaresis J, Chinnasamy H, Ehlinger Z, Reynolds W, Lynn R, Rotiroti MC, Gkitsas N, Arai S, Johnston L, Lowsky R, Majzner RG, Meyer E, Negrin RS, Rezvani AR, Sidana S, Shizuru J, Weng WK, Mullins C, Jacob A, Kirsch I, Bazzano M, Zhou J, Mackay S, Bornheimer SJ, Schultz L, Ramakrishna S, Davis KL, Kong KA, Shah NN, Qin H, Fry T, Feldman S, Mackall CL, Miklos DB. Spiegel JY, et al. Among authors: kirsch i. Nat Med. 2021 Aug;27(8):1419-1431. doi: 10.1038/s41591-021-01436-0. Epub 2021 Jul 26. Nat Med. 2021. PMID: 34312556 Free PMC article. Clinical Trial.
Implications of Placebo and Nocebo Effects for Clinical Practice: Expert Consensus.
Evers AWM, Colloca L, Blease C, Annoni M, Atlas LY, Benedetti F, Bingel U, Büchel C, Carvalho C, Colagiuri B, Crum AJ, Enck P, Gaab J, Geers AL, Howick J, Jensen KB, Kirsch I, Meissner K, Napadow V, Peerdeman KJ, Raz A, Rief W, Vase L, Wager TD, Wampold BE, Weimer K, Wiech K, Kaptchuk TJ, Klinger R, Kelley JM. Evers AWM, et al. Among authors: kirsch i. Psychother Psychosom. 2018;87(4):204-210. doi: 10.1159/000490354. Epub 2018 Jun 12. Psychother Psychosom. 2018. PMID: 29895014 Free PMC article.
Reply.
Carvalho C, Kirsch I, Kaptchuk TJ. Carvalho C, et al. Among authors: kirsch i. Pain. 2017 Mar;158(3):536-537. doi: 10.1097/j.pain.0000000000000795. Pain. 2017. PMID: 28187105 No abstract available.
What are the treatment remission, response and extent of improvement rates after up to four trials of antidepressant therapies in real-world depressed patients? A reanalysis of the STAR*D study's patient-level data with fidelity to the original research protocol.
Pigott HE, Kim T, Xu C, Kirsch I, Amsterdam J. Pigott HE, et al. Among authors: kirsch i. BMJ Open. 2023 Jul 25;13(7):e063095. doi: 10.1136/bmjopen-2022-063095. BMJ Open. 2023. PMID: 37491091 Free PMC article.
An instructive role for Interleukin-7 receptor α in the development of human B-cell precursor leukemia.
Geron I, Savino AM, Fishman H, Tal N, Brown J, Turati VA, James C, Sarno J, Hameiri-Grossman M, Lee YN, Rein A, Maniriho H, Birger Y, Zemlyansky A, Muler I, Davis KL, Marcu-Malina V, Mattson N, Parnas O, Wagener R, Fischer U, Barata JT, Jamieson CHM, Müschen M, Chen CW, Borkhardt A, Kirsch IR, Nagler A, Enver T, Izraeli S. Geron I, et al. Among authors: kirsch ir. Nat Commun. 2022 Feb 3;13(1):659. doi: 10.1038/s41467-022-28218-7. Nat Commun. 2022. PMID: 35115489 Free PMC article.
CRLF2-rearranged B-cell ALL with extramedullary lineage switch to AML following CD19-targeted therapy.
Silbert SK, Scanlon S, Wang HW, Yuan CM, Doverte A, Wellek J, Patel N, Braylan R, Ahlman M, Turkbey EB, Bohling SD, Chisholm KM, Oztek MA, LaLoggia M, Verma A, Shalabi H, Kovach AE, Wood BL, Lamble A, Kirsch I, Leger K, Shah NN. Silbert SK, et al. Among authors: kirsch i. J Immunother Cancer. 2024 Oct 26;12(10):e009499. doi: 10.1136/jitc-2024-009499. J Immunother Cancer. 2024. PMID: 39461880 Free PMC article.
Response Expectancy and the Placebo Effect.
Kirsch I. Kirsch I. Int Rev Neurobiol. 2018;138:81-93. doi: 10.1016/bs.irn.2018.01.003. Epub 2018 Feb 28. Int Rev Neurobiol. 2018. PMID: 29681336 Review.
Challenges to Using Big Data in Cancer.
Sweeney SM, Hamadeh HK, Abrams N, Adam SJ, Brenner S, Connors DE, Davis GJ, Fiore L, Gawel SH, Grossman RL, Hanlon SE, Hsu K, Kelloff GJ, Kirsch IR, Louv B, McGraw D, Meng F, Milgram D, Miller RS, Morgan E, Mukundan L, O'Brien T, Robbins P, Rubin EH, Rubinstein WS, Salmi L, Schaller T, Shi G, Sigman CC, Srivastava S. Sweeney SM, et al. Among authors: kirsch ir. Cancer Res. 2023 Apr 14;83(8):1175-1182. doi: 10.1158/0008-5472.CAN-22-1274. Cancer Res. 2023. PMID: 36625843 Free PMC article. Review.
439 results